Sofosbuvir (Indonesian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Sofosbuvir" in Indonesian language version.

refsWebsite

Global rank Indonesian rank

17nih.gov

4^th place

13^th place

15web.archive.org

1^st place

12doi.org

2^nd place

4^th place

6fda.gov

447^th place

792^nd place

5nytimes.com

7^th place

35^th place

2medicines.org.uk

3,823^rd place

9,839^th place

2who.int

195^th place

203^rd place

2fiercepharma.com

low place

2bloomberg.com

99^th place

159^th place

2ctaf.org

low place

1drugs.com

399^th place

480^th place

1uw.edu

low place

1newyorker.com

146^th place

884^th place

1mercurynews.com

701^st place

1,609^th place

1hcvguidelines.org

low place

1worldcat.org

5^th place

7^th place

1jbc.org

4,455^th place

2,929^th place

1medscape.com

719^th place

1,112^th place

1wsj.com

79^th place

211^th place

1forbes.com

54^th place

61^st place

1theguardian.com

12^th place

49^th place

1reuters.com

49^th place

96^th place

1doctorsoftheworld.org

low place

1dddmag.com

low place

1pppmag.com

low place

1seekingalpha.com

5,344^th place

5,989^th place

1deindoktor.ch

low place

1hsj.co.uk

low place

1asiae.co.kr

905^th place

179^th place

1edaily.co.kr

3,640^th place

1,352^nd place

1accesstomedicineindex.org

low place

1amfar.org

low place

1dndi.org

low place

1medecinsdumonde.org

low place

1epo.org

low place

1spiegel.de

66^th place

898^th place

1lemonde.fr

83^rd place

2,437^th place

1firstwordpharma.com

low place

1sciencedirect.com

149^th place

229^th place

1archive.today

14^th place

30^th place

1sagepub.com

731^st place

844^th place

1yixiblog.wordpress.com

low place

accesstomedicineindex.org

"Pricing, Manufacturing & Distribution | Access to Medicine Index 2014". Diarsipkan dari versi asli tanggal 2015-02-06. Diakses tanggal 2017-06-08.

amfar.org

amfAR Feb. 2015 Hepatitis C and Drug Pricing: The Need for a Better Balance Diarsipkan 2016-04-07 di Wayback Machine.

archive.today

Smith, Michael (December 16, 2014). "Interferon-/Ribavirin-Free Regimen for Chronic Hepatitis C Virus Infection". Annals of Pharmacotherapy. 49 (3): 343–50. doi:10.1177/1060028014563952. PMID 25515863. Diarsipkan dari versi asli tanggal 2015-02-27. Diakses tanggal 2017-06-08.

asiae.co.kr

view.asiae.co.kr

"C형간염 치료제 건강보험 적용". Diakses tanggal 2 August 2016.

bloomberg.com

Armstrong, Drew (21 March 2014). "Gilead's $84,000 Treatment Questioned by U.S. Lawmakers". Bloomberg. Diakses tanggal 27 October 2015.
Einhorn, Bruce. "How India's Patent Office Destroyed Gilead's Global Game Plan". Bloomberg.com. Diakses tanggal 2015-12-30.

ctaf.org

"New Lower Prices for Gilead Hepatitis C Drugs Reach CTAF Threshold for High Health System Value" (Siaran pers). 2015-02-17. Diakses tanggal 2015-02-22. "Salinan arsip". Diarsipkan dari versi asli tanggal 2015-02-22. Diakses tanggal 2017-06-08.
California Technology Assessment Forum (2014-03-10). "Treatments for Hepatitis C". Diarsipkan dari versi asli tanggal 2014-10-20. Diakses tanggal 2017-06-08.

dddmag.com

Staff (December 11, 2014). "Gilead Faces Lawsuit Over Hepatitis C Drug Pricing". Drug Discovery & Development. United States: Advantage Business Media. Associated Press.

deindoktor.ch

"Sovaldi / Sofosbuvir medication in Switzerland". Diarsipkan dari versi asli tanggal 2016-10-04. Diakses tanggal 2017-06-08.

dndi.org

Drugs for Neglected Diseases Initiative April 2016 An Alternative Research and Development Strategy to Deliver Affordable Treatments for Hepatitis C Patients

doctorsoftheworld.org

Waldman, Ron. "Gilead's HCV drug sofosbuvir approved by the FDA but accessible for how many?" (PDF). Doctors of the World. Diarsipkan dari versi asli (PDF) tanggal 2014-02-26. Diakses tanggal 22 February 2014.

doi.org

Calvaruso V, Mazza M, Almasio PL (May 2011). "Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects". Expert Opin Drug Saf. 10 (3): 429–35. doi:10.1517/14740338.2011.559161. PMID 21323500.
Bhatia, Harmeet Kaur; Singh, Harmanjit; Grewal, Nipunjot; Natt, Navreet Kaur (2014-01-01). "Sofosbuvir: A novel treatment option for chronic hepatitis C infection". Journal of Pharmacology & Pharmacotherapeutics. 5 (4): 278–284. doi:10.4103/0976-500X.142464. ISSN 0976-500X. PMC 4231565 . PMID 25422576.
Karageorgopoulos, Drosos E.; El-Sherif, Omar; Bhagani, Sanjay; Khoo, Saye H. (February 2014). "Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection". Current Opinion in Infectious Diseases. 27 (1): 36–45. doi:10.1097/QCO.0000000000000034. PMID 24305043.
Pol, Stanislas; Vallet-Pichard, Anaïs; Corouge, Marion (March 2016). "Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life". Hepatic Medicine: Evidence and Research. 8: 21–6. doi:10.2147/HMER.S62014. PMC 4786064 . PMID 27019602.
Fung, A; Jin, Z; Dyatkina, N; Wang, G; Beigelman, L; Deval, J (2014). "Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase". Antimicrobial Agents and Chemotherapy. 58 (7): 3636–45. doi:10.1128/AAC.02666-14. PMC 4068585 . PMID 24733478.
Ma, H.; Jiang, W.-R.; Robledo, N.; Leveque, V.; Ali, S.; Lara-Jaime, T.; Masjedizadeh, M.; Smith, D. B.; Cammack, N.; Klumpp, K.; Symons, J. (2007). "Characterization of the Metabolic Activation of Hepatitis C Virus Nucleoside Inhibitor β-d-2′-Deoxy-2′-fluoro-2′-C-methylcytidine (PSI-6130) and Identification of a Novel Active 5′-Triphosphate Species". The Journal of Biological Chemistry. 282 (41): 29812–29820. doi:10.1074/jbc.M705274200. PMID 17698842.
Kirby, Brian J.; Symonds, William T.; Kearney, Brian P.; Mathias, Anita A. (2015-03-31). "Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir". Clinical Pharmacokinetics (dalam bahasa Inggris). 54 (7): 677–690. doi:10.1007/s40262-015-0261-7. PMID 25822283.
"Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977". J. Biol. Chem. 285 (45): 34337–47. November 2010. doi:10.1074/jbc.M110.161802. PMC 2966047 . PMID 20801890.
"Minimum target prices for production of direct acting antivirals and associated diagnostics to combat Hepatitis C Virus". Hepatology. 61 (4): 1174–82. December 2014. doi:10.1002/hep.27641. PMC 4403972 . PMID 25482139.
Childs-Kean, Lindsey (January 16, 2015). "Simeprevir and Sofosbuvir for Treatment of Chronic Hepatitis C Infection". Clinical Therapeutics. 37 (2): 243–67. doi:10.1016/j.clinthera.2014.12.012. PMID 25601269.
Smith, Michael (December 16, 2014). "Interferon-/Ribavirin-Free Regimen for Chronic Hepatitis C Virus Infection". Annals of Pharmacotherapy. 49 (3): 343–50. doi:10.1177/1060028014563952. PMID 25515863. Diarsipkan dari versi asli tanggal 2015-02-27. Diakses tanggal 2017-06-08.
Murakami, E.; Tolstykh, T.; Bao, H.; Niu, C.; Steuer, H. M. M.; Bao, D.; Chang, W.; Espiritu, C.; Bansal, S. (26 August 2010). "Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977". Journal of Biological Chemistry. 285 (45): 34337–34347. doi:10.1074/jbc.M110.161802. PMC 2966047 . PMID 20801890.

drugs.com

"Sofosbuvir". The American Society of Health-System Pharmacists. Diakses tanggal Nov 30, 2016.

edaily.co.kr

무단전재, Ⓒ 종합 경제정보 미디어 이데일리-상업적; 금지, 재배포 (20 April 2016). "C형 간염 치료제 신약, 내달 1일부터 건강보험 적용". Diarsipkan dari versi asli tanggal 2016-05-31. Diakses tanggal 2 August 2016.

epo.org

register.epo.org

"European Patent EP2203462, granted 21 May 2014". European Patent Register. European Patent Office. Diakses tanggal 12 February 2015.

fda.gov

accessdata.fda.gov

"Sofosbuvir label" (PDF). FDA. August 2015.
"Copegus (Ribavirin, USP Tablets) Medication Guide" (PDF). Roche. Diakses tanggal 28 October 2014.
"Application Number: 204671Orig1s000: Medical Reviews" (PDF). FDA. November 20, 2013.

fda.gov

"Direct-Acting Antivirals for Hepatitis C: Drug Safety Communication - Risk of Hepatitis B Reactivating". FDA. 4 October 2016. Diakses tanggal 6 October 2016.
"FDA approves Sovaldi for chronic hepatitis C". FDA New Release. U.S. Food and Drug Administration. 2013-12-06.
"FDA approves first combination pill to treat hepatitis C".

fiercepharma.com

Stanton, Tracy. "Activists pounce on $1,000-a-day price for Gilead's hep C wonder drug, Sovaldi". FiercePharma. Fierce. Diarsipkan dari versi asli tanggal 2014-02-18. Diakses tanggal 22 February 2014.
"Gilead strikes Sovaldi price deal in Germany as it picks up speed in EU". Diarsipkan dari versi asli tanggal 2015-02-19. Diakses tanggal 2017-06-08.

firstwordpharma.com

"Charity challenges Gilead's European patent on hepatitis C therapy Sovaldi". February 10, 2015. Diakses tanggal March 4, 2015.

forbes.com

Herper, Matthew (February 21, 2014). "Gilead's Hepatitis C Pill Takes Off Like A Rocket". Forbes.

hcvguidelines.org

"Recommendations for Testing, Managing, and Treating Hepatitis C" (PDF). AASLD/IDSA. 27 September 2016. Diarsipkan dari versi asli (PDF) tanggal 2016-11-10. Diakses tanggal 10 November 2016.

hsj.co.uk

"NHS England rollout of ground-breaking drugs 'changes role of NICE'". Health Service Journal. 4 April 2016. Diakses tanggal 14 May 2016.

jbc.org

Ma, H.; Jiang, W.-R.; Robledo, N.; Leveque, V.; Ali, S.; Lara-Jaime, T.; Masjedizadeh, M.; Smith, D. B.; Cammack, N.; Klumpp, K.; Symons, J. (2007). "Characterization of the Metabolic Activation of Hepatitis C Virus Nucleoside Inhibitor β-d-2′-Deoxy-2′-fluoro-2′-C-methylcytidine (PSI-6130) and Identification of a Novel Active 5′-Triphosphate Species". The Journal of Biological Chemistry. 282 (41): 29812–29820. doi:10.1074/jbc.M705274200. PMID 17698842.

lemonde.fr

"Conflit autour d'un traitement contre l'hépatite C" (dalam bahasa French). February 10, 2015. Diakses tanggal March 4, 2015.

medecinsdumonde.org

"DOCTORS OF THE WORLD—MÉDECINS DU MONDE OPPOSES SOFOSBUVIR PATENT IN EUROPE". Médecins du Monde. Diarsipkan dari versi asli tanggal 2015-02-12. Diakses tanggal 12 February 2015.

medicines.org.uk

"Sovaldi 400 mg film coated tablets - Summary of Product Characteristics (SPC) - (eMC)". www.medicines.org.uk. Diarsipkan dari versi asli tanggal 2016-11-10. Diakses tanggal 8 January 2017.
"Sovaldi 400 mg film coated tablets - Summary of Product Characteristics". UK Electronic Medicines Compendium. September 2016. Diarsipkan dari versi asli tanggal 2016-11-10. Diakses tanggal 10 November 2016.

medscape.com

Tucker M (December 6, 2013). "FDA Approves 'Game Changer' Hepatitis C Drug Sofosbuvir". Medscape.

mercurynews.com

Associated Press; Alonso-Zaldivar, Ricardo (July 29, 2014). "Gilead's Sovaldi prescribed more than all other hepatitis C drugs combined – The Mercury News". Mercury News.

newyorker.com

Gounder, Celine (9 December 2013). "A Better Treatment for Hepatitis C". The New Yorker.

nih.gov

ncbi.nlm.nih.gov

Hill, A; Simmons, B; Gotham, D; Fortunak, J (1 January 2016). "Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C". Journal of virus eradication. 2 (1): 28–31. PMC 4946692 . PMID 27482432.
Berden FA, Kievit W, Baak LC, et al. (October 2014). "Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era". Neth J Med. 72 (8): 388–400. PMID 25387551.
Cholongitas E, Papatheodoridis GV (2014). "Sofosbuvir: a novel oral agent for chronic hepatitis C". Ann Gastroenterol. 27 (4): 331–337. PMC 4188929 . PMID 25332066.
Tran TT (December 2012). "A review of standard and newer treatment strategies in hepatitis C". Am J Manag Care. 18 (14 Suppl): S340–9. PMID 23327540.
Yau AH, Yoshida EM (September 2014). "Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review". Can J Gastroenterol Hepatol. 28 (8): 445–51. PMC 4210236 . PMID 25229466.
Calvaruso V, Mazza M, Almasio PL (May 2011). "Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects". Expert Opin Drug Saf. 10 (3): 429–35. doi:10.1517/14740338.2011.559161. PMID 21323500.
Bhatia, Harmeet Kaur; Singh, Harmanjit; Grewal, Nipunjot; Natt, Navreet Kaur (2014-01-01). "Sofosbuvir: A novel treatment option for chronic hepatitis C infection". Journal of Pharmacology & Pharmacotherapeutics. 5 (4): 278–284. doi:10.4103/0976-500X.142464. ISSN 0976-500X. PMC 4231565 . PMID 25422576.
Karageorgopoulos, Drosos E.; El-Sherif, Omar; Bhagani, Sanjay; Khoo, Saye H. (February 2014). "Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection". Current Opinion in Infectious Diseases. 27 (1): 36–45. doi:10.1097/QCO.0000000000000034. PMID 24305043.
Pol, Stanislas; Vallet-Pichard, Anaïs; Corouge, Marion (March 2016). "Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life". Hepatic Medicine: Evidence and Research. 8: 21–6. doi:10.2147/HMER.S62014. PMC 4786064 . PMID 27019602.
Fung, A; Jin, Z; Dyatkina, N; Wang, G; Beigelman, L; Deval, J (2014). "Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase". Antimicrobial Agents and Chemotherapy. 58 (7): 3636–45. doi:10.1128/AAC.02666-14. PMC 4068585 . PMID 24733478.
Ma, H.; Jiang, W.-R.; Robledo, N.; Leveque, V.; Ali, S.; Lara-Jaime, T.; Masjedizadeh, M.; Smith, D. B.; Cammack, N.; Klumpp, K.; Symons, J. (2007). "Characterization of the Metabolic Activation of Hepatitis C Virus Nucleoside Inhibitor β-d-2′-Deoxy-2′-fluoro-2′-C-methylcytidine (PSI-6130) and Identification of a Novel Active 5′-Triphosphate Species". The Journal of Biological Chemistry. 282 (41): 29812–29820. doi:10.1074/jbc.M705274200. PMID 17698842.
Kirby, Brian J.; Symonds, William T.; Kearney, Brian P.; Mathias, Anita A. (2015-03-31). "Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir". Clinical Pharmacokinetics (dalam bahasa Inggris). 54 (7): 677–690. doi:10.1007/s40262-015-0261-7. PMID 25822283.
"Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977". J. Biol. Chem. 285 (45): 34337–47. November 2010. doi:10.1074/jbc.M110.161802. PMC 2966047 . PMID 20801890.
"Minimum target prices for production of direct acting antivirals and associated diagnostics to combat Hepatitis C Virus". Hepatology. 61 (4): 1174–82. December 2014. doi:10.1002/hep.27641. PMC 4403972 . PMID 25482139.
Childs-Kean, Lindsey (January 16, 2015). "Simeprevir and Sofosbuvir for Treatment of Chronic Hepatitis C Infection". Clinical Therapeutics. 37 (2): 243–67. doi:10.1016/j.clinthera.2014.12.012. PMID 25601269.
Smith, Michael (December 16, 2014). "Interferon-/Ribavirin-Free Regimen for Chronic Hepatitis C Virus Infection". Annals of Pharmacotherapy. 49 (3): 343–50. doi:10.1177/1060028014563952. PMID 25515863. Diarsipkan dari versi asli tanggal 2015-02-27. Diakses tanggal 2017-06-08.
Murakami, E.; Tolstykh, T.; Bao, H.; Niu, C.; Steuer, H. M. M.; Bao, D.; Chang, W.; Espiritu, C.; Bansal, S. (26 August 2010). "Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977". Journal of Biological Chemistry. 285 (45): 34337–34347. doi:10.1074/jbc.M110.161802. PMC 2966047 . PMID 20801890.

nytimes.com

Harris, Gardiner (15 September 2014). "Maker of Costly Hepatitis C Drug Sovaldi Strikes Deal on Generics for Poor Countries". The New York Times.
Pollack, Andrew (October 10, 2014). "Harvoni, a Hepatitis C Drug from Gilead, Wins F.D.A. Approval". The New York Times.
Pollack, Andrew (December 6, 2013). "F. D. A. Approves Pill to Treat Hepatitis". The New York Times.
"Medical Groups Question Price of New Hep C Drug". The New York Times. Associated Press. 11 March 2014. ^{[pranala nonaktif permanen]}
"High Cost of Sovaldi Hepatitis C Drug Prompts a Call to Void Its Patents - The New York Times".

pppmag.com

Lucio, Steven (February 2015). "The Increasing Impact of High-Cost Specialty Therapies". Pharmacy Purchasing & Products Magazine. Diarsipkan dari versi asli tanggal 2015-12-08. Diakses tanggal 4 December 2015.

reuters.com

in.reuters.com

Kalra, Aditya; Siddiqui, Zeba (September 15, 2014). "Gilead licenses hepatitis C drug to Cipla, Ranbaxy, five others". Reuters India (dalam bahasa Inggris). Diarsipkan dari versi asli tanggal 2014-12-10. Diakses tanggal 2017-06-08. CS1 maint: Unrecognized language (link)

sagepub.com

aop.sagepub.com

Smith, Michael (December 16, 2014). "Interferon-/Ribavirin-Free Regimen for Chronic Hepatitis C Virus Infection". Annals of Pharmacotherapy. 49 (3): 343–50. doi:10.1177/1060028014563952. PMID 25515863. Diarsipkan dari versi asli tanggal 2015-02-27. Diakses tanggal 2017-06-08.

sciencedirect.com

Childs-Kean, Lindsey (January 16, 2015). "Simeprevir and Sofosbuvir for Treatment of Chronic Hepatitis C Infection". Clinical Therapeutics. 37 (2): 243–67. doi:10.1016/j.clinthera.2014.12.012. PMID 25601269.

seekingalpha.com

"Gilead Q4 2014 Earnings Call".

spiegel.de

Nicola Kuhrt (February 10, 2015). "Hepatitis-Pille Sovaldi: "Ärzte der Welt" geht gegen Patent vor" (dalam bahasa German). Der Spiegel. Diakses tanggal February 10, 2015.

theguardian.com

Boseley, Sarah (15 January 2015). "Hepatitis C drug delayed by NHS due to high cost". The Guardian.

uw.edu

hepatitisc.uw.edu

"Sofosbuvir (Sovaldi) - Treatment - Hepatitis C Online". www.hepatitisc.uw.edu. Diakses tanggal 8 January 2017.

web.archive.org

"Sovaldi 400 mg film coated tablets - Summary of Product Characteristics (SPC) - (eMC)". www.medicines.org.uk. Diarsipkan dari versi asli tanggal 2016-11-10. Diakses tanggal 8 January 2017.
"Sovaldi 400 mg film coated tablets - Summary of Product Characteristics". UK Electronic Medicines Compendium. September 2016. Diarsipkan dari versi asli tanggal 2016-11-10. Diakses tanggal 10 November 2016.
"Recommendations for Testing, Managing, and Treating Hepatitis C" (PDF). AASLD/IDSA. 27 September 2016. Diarsipkan dari versi asli (PDF) tanggal 2016-11-10. Diakses tanggal 10 November 2016.
Kalra, Aditya; Siddiqui, Zeba (September 15, 2014). "Gilead licenses hepatitis C drug to Cipla, Ranbaxy, five others". Reuters India (dalam bahasa Inggris). Diarsipkan dari versi asli tanggal 2014-12-10. Diakses tanggal 2017-06-08. CS1 maint: Unrecognized language (link)
Stanton, Tracy. "Activists pounce on $1,000-a-day price for Gilead's hep C wonder drug, Sovaldi". FiercePharma. Fierce. Diarsipkan dari versi asli tanggal 2014-02-18. Diakses tanggal 22 February 2014.
Waldman, Ron. "Gilead's HCV drug sofosbuvir approved by the FDA but accessible for how many?" (PDF). Doctors of the World. Diarsipkan dari versi asli (PDF) tanggal 2014-02-26. Diakses tanggal 22 February 2014.
Lucio, Steven (February 2015). "The Increasing Impact of High-Cost Specialty Therapies". Pharmacy Purchasing & Products Magazine. Diarsipkan dari versi asli tanggal 2015-12-08. Diakses tanggal 4 December 2015.
"New Lower Prices for Gilead Hepatitis C Drugs Reach CTAF Threshold for High Health System Value" (Siaran pers). 2015-02-17. Diakses tanggal 2015-02-22. "Salinan arsip". Diarsipkan dari versi asli tanggal 2015-02-22. Diakses tanggal 2017-06-08.
California Technology Assessment Forum (2014-03-10). "Treatments for Hepatitis C". Diarsipkan dari versi asli tanggal 2014-10-20. Diakses tanggal 2017-06-08.
"Gilead strikes Sovaldi price deal in Germany as it picks up speed in EU". Diarsipkan dari versi asli tanggal 2015-02-19. Diakses tanggal 2017-06-08.
"Sovaldi / Sofosbuvir medication in Switzerland". Diarsipkan dari versi asli tanggal 2016-10-04. Diakses tanggal 2017-06-08.
"Pricing, Manufacturing & Distribution | Access to Medicine Index 2014". Diarsipkan dari versi asli tanggal 2015-02-06. Diakses tanggal 2017-06-08.
amfAR Feb. 2015 Hepatitis C and Drug Pricing: The Need for a Better Balance Diarsipkan 2016-04-07 di Wayback Machine.
"DOCTORS OF THE WORLD—MÉDECINS DU MONDE OPPOSES SOFOSBUVIR PATENT IN EUROPE". Médecins du Monde. Diarsipkan dari versi asli tanggal 2015-02-12. Diakses tanggal 12 February 2015.

who.int

"WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Diakses tanggal 8 December 2016.
"Essential Medicines WHO Model List, 19th edition, April 2015" (PDF). World Health Organization. 2015.

worldcat.org

Bhatia, Harmeet Kaur; Singh, Harmanjit; Grewal, Nipunjot; Natt, Navreet Kaur (2014-01-01). "Sofosbuvir: A novel treatment option for chronic hepatitis C infection". Journal of Pharmacology & Pharmacotherapeutics. 5 (4): 278–284. doi:10.4103/0976-500X.142464. ISSN 0976-500X. PMC 4231565 . PMID 25422576.

wsj.com

"Hepatitis C Dilemma: Treat Illness With Interferon Now or Wait? - WSJ".

yixiblog.wordpress.com

"Comparison of tenofovir prodrugs: TAF vs TDF". DRUG R&D INSIGHT. Diakses tanggal 24 November 2015.